Literature DB >> 30060226

Primary Hyperparathyroidism.

John P Bilezikian1.   

Abstract

Background: Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women. The clinical presentation of PHPT has evolved over the past 40 years to include three distinct clinical phenotypes, each of which has been studied in detail and has led to evolving concepts about target organ involvement, natural history, and management.
Methods: In the present review, I provide an evidence-based summary of this disorder as it has been studied worldwide, citing key concepts and data that have helped to shape our concepts about this disease.
Results: PHPT is now recognized to include three clinical phenotypes: overt target organ involvement, mild asymptomatic hypercalcemia, and high PTH levels with persistently normal albumin-corrected and ionized serum calcium values. The factors that determine which of these clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is used, vitamin D deficiency is present, and whether parathyroid hormone levels are routinely measured in the evaluation of low bone density or frank osteoporosis. Guidelines for parathyroidectomy apply to all three clinical forms of the disease. If surgical guidelines are not met, parathyroidectomy can also be an appropriate option if no medical contraindications are present. If either the serum calcium or bone mineral density is of concern and surgery is not an option, pharmacological approaches are available and effective. Conclusions: Advances in our knowledge of PHPT have guided new concepts in diagnosis and management.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30060226      PMCID: PMC6182311          DOI: 10.1210/jc.2018-01225

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  107 in total

Review 1.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

2.  Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.

Authors:  Jian-Min Liu; Natalie E Cusano; Barbara C Silva; Lin Zhao; Xiao-Yan He; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Wen-Wei Fan; Megan E Romano; Guang Ning; John P Bilezikian
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

3.  The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism.

Authors:  Robert Udelsman; Zhenqiu Lin; Patricia Donovan
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

4.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

5.  Use of Calcium and Parathyroid Hormone Nomogram to Distinguish Between Atypical Primary Hyperparathyroidism and Normal Patients.

Authors:  Olga A Lavryk; Allan E Siperstein
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

6.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

7.  Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study).

Authors:  Karolina Lundstam; Ansgar Heck; Kristin Godang; Charlotte Mollerup; Marek Baranowski; Ylva Pernow; Turid Aas; Ola Hessman; Thord Rosén; Jörgen Nordenström; Svante Jansson; Mikael Hellström; Jens Bollerslev
Journal:  J Bone Miner Res       Date:  2017-07-07       Impact factor: 6.741

8.  Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism.

Authors:  J H Lee; J H Kim; A R Hong; S W Kim; C S Shin
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

9.  Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.

Authors:  Symeon Tournis; Eleni Fakidari; Ismene Dontas; Chrysoula Liakou; Julia Antoniou; Antonis Galanos; Helen Marketou; Konstantinos Makris; Katerina Katsalira; George Trovas; George P Lyritis; Nikolaos Papaioannou
Journal:  J Bone Miner Metab       Date:  2013-05-23       Impact factor: 2.626

10.  Physical Activity and the Risk of Primary Hyperparathyroidism.

Authors:  Anand Vaidya; Gary C Curhan; Julie M Paik; Molin Wang; Eric N Taylor
Journal:  J Clin Endocrinol Metab       Date:  2016-01-26       Impact factor: 5.958

View more
  45 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

2.  Hypercalcemia caused by comorbid parathyroid adenoma and pulmonary tuberculosis.

Authors:  Sahoko Kamejima; Izumi Yamamoto; Arisa Kobayashi; Akio Nakashima; Taketo Uchiyama; Ichiro Ohkido; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2020-07-06

3.  Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota.

Authors:  Jau-Yi Li; Mingcan Yu; Subhashis Pal; Abdul Malik Tyagi; Hamid Dar; Jonathan Adams; M Neale Weitzmann; Rheinallt M Jones; Roberto Pacifici
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  Evaluating Patients for Secondary Causes of Osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Curr Osteoporos Rep       Date:  2022-01-15       Impact factor: 5.096

5.  The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Maryam Yavari; Awat Feizi; Fahimeh Haghighatdoost; Azin Ghaffari; Hassan Rezvanian
Journal:  Endocrine       Date:  2020-10-15       Impact factor: 3.633

6.  The Potential Role of Preoperative Trabecular Bone Score in Predicting Changes in Bone Mineral Density After Parathyroidectomy.

Authors:  David Tak Wai Lui; Matrix Man Him Fung; Chi Ho Lee; Carol Ho Yi Fong; Connie Hong Nin Loong; Allan Hoi Kin Lam; Kathryn Choon Beng Tan; Yu Cho Woo; Brian Hung Hin Lang
Journal:  World J Surg       Date:  2020-10-26       Impact factor: 3.352

Review 7.  The Gut Microbiome and Bone Strength.

Authors:  Macy Castaneda; Jasmin M Strong; Denise A Alabi; Christopher J Hernandez
Journal:  Curr Osteoporos Rep       Date:  2020-10-08       Impact factor: 5.096

8.  Primary hyperparathyroidism in pregnancy: observations from the Indian PHPT registry.

Authors:  R Pal; S K Bhadada; N Gupta; A Behera; N Aggarwal; A Aggarwal; K V Raviteja; U N Saikia; G Kaur; S M Arvindbhai; R Walia
Journal:  J Endocrinol Invest       Date:  2020-10-09       Impact factor: 4.256

9.  Delayed Calcium Normalization after Successful Parathyroidectomy in Primary Hyperparathyroidism.

Authors:  Iván Emilio de la Cruz Rodríguez; Elsy Sarahí García Montesinos; María Fernanda Rodríguez-Delgado; Guadalupe Vargas Ortega; Lourdes Balcázar Hernández; Victoria Mendoza Zubieta; Victor Hernández Avendaño; Baldomero González Virla
Journal:  Case Rep Endocrinol       Date:  2021-04-23

10.  Total and free vitamin D metabolites in patients with primary hyperparathyroidism.

Authors:  L Meng; C Su; S A Shapses; X Wang
Journal:  J Endocrinol Invest       Date:  2021-07-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.